Type: Securities Fraud case filed

According to the Complaint, the Company made false and misleading statements to the market. Match used fake messages of interest to lure customers into buying subscriptions and upgrades. At the same time, the Company made it difficult and confusing for customers to cancel subscriptions. The Company also lacked appropriate controls on disclosure. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Match, investors suffered damages.

.

According to the Complaint, the Company made false and misleading statements to the market. Ollie’s failed to build and maintain an effective supply chain system, impacting the availability of inventory for new stores. The Company failed to maintain sufficient inventory to meet demand at certain stores. Based on these facts, the Company’s comparable-store sales were likely to decrease in sequential quarters. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Ollie’s, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. ProPetro’s executives were improperly reimbursed for various expenses. The Company also engaged in undisclosed related-party transactions. The Company failed to maintain sufficient disclosure controls and procedures while lacking effective controls on financial reporting at the same time. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about ProPetro, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Customer demand for ViewRay systems suffered declines partially due to Medicare reimbursement changes announced in November 2018, which made the Company’s systems less profitable for their users. The Company overstated its backlog by including orders that lacked the surety required to include them on the backlog. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about ViewRay, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Tencent Music created exclusive licensing deals with record labels that were anticompetitive. The deals made sublicensing content from the Company extremely expensive, to the point of violating Chinese law. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Tencent Music, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Meredith overinflated the profitability of the Time Inc. merger. In fact, the Company was forced to make significant investments in the Time business to improve it. These investments negatively impacted the Company’s earnings. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Meredith, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Eldorado CEO Thomas Reeg and other executives participated in improper trading in the securities of a separate publicly traded company. Based on this fact, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Eldorado, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Sarepta’s therapy golodirsen posed serious safety risks to patients. These risks made it unlikely that the FDA would approve the Company’s NDA package for accelerated approval for golodirsen. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Sarepta, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. When the market learned the truth about AmTrust, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. MacroGenics had conducted a progression-free survival (“PFS”) and first interim overall survival (“OS”) analyses for the SOPHIA trial by October 10, 2018. This analysis showed a 0.9 month improvement in PFS. The interim OS analysis did not demonstrate a statistically significant result and the interim OS Kaplan-Meier curves (a non-parametric statistic used to estimate the survival function from lifetime data) crossed in several spots (thereby violating the constant hazard assumption) before separating late. Based on these facts, the Company’s public statements were false and misleading throughout the class period. When the market learned the truth about MacroGenics, investors suffered damages.